Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06447623

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Study of Efficacy of Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Advanced Breast Cancer (Open, Randomized, Phase III)

Sponsor: Fudan University

Conditions Advanced Breast Cancer HR+/HER2- Breast Cancer

Interventions Apatinib Aromatase inhibitor and Fulvestrant CDK4/6 Inhibitor

Updated 2 times since 2024 Last updated: Jun 3, 2024 Started: Feb 1, 2024 Primary completion: Feb 1, 2027 Completion: Feb 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06447623, this PHASE3 trial focuses on Advanced Breast Cancer and HR+/HER2- Breast Cancer and remains actively recruiting participants. Sponsored by Fudan University, it has been updated 2 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3

First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China